Product Information for the Patient
Rivastigmina Sandoz 1.5mg Hard Capsules EFG
Rivastigmina Sandoz 3mg Hard Capsules EFG
Rivastigmina Sandoz 4.5mg Hard Capsules EFG
Rivastigmina Sandoz 6mg Hard Capsules EFG
rivastigmina
Read this entire leaflet carefully before you start taking this medicine, because it contains important information for you.
1.What is Rivastigmina Sandoz and what is it used for
2.What you need to knowbefore you start taking Rivastigmina Sandoz
3.How to take Rivastigmina Sandoz
4.Possible side effects
5.Storage of Rivastigmina Sandoz
6.Contents of the pack and additional information
The active ingredient of Rivastigmina Sandoz is rivastigmina.
Rivastigmina belongs to a group of substances called cholinesterase inhibitors. In patients with Alzheimer's disease or dementia due to Parkinson's disease, certain nerve cells in the brain die, resulting in a reduction of acetylcholine neurotransmitter levels (a substance that allows communication between nerve cells). Rivastigmina blocks the enzymes that destroy acetylcholine: acetylcholinesterase and butyrylcholinesterase. By blocking these enzymes, Rivastigmina Sandoz allows acetylcholine levels in the brain to increase, helping to reduce the symptoms of Alzheimer's disease and dementia associated with Parkinson's disease.
Rivastigmina Sandoz is used for the treatment of adult patients with mild to moderately severe Alzheimer's disease, a progressive brain disorder that gradually affects memory, intellectual capacity, and behavior. The capsules and oral solution can also be used for the treatment of dementia in adult patients with Parkinson's disease.
Do not take Rivastigmina Sandoz
If you are in any of these situations, inform your doctor and do not take Rivastigmina Sandoz.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Rivastigmina Sandoz
If you are in any of these situations, your doctor may need to monitor you more closely while you are being treated.
If you have not taken Rivastigmina Sandoz for more than three days, do not take the next dose until you have spoken with your doctor.
Rivastigmina Sandoz is not recommended for use in children or adolescents (under 18 years old).
Children and adolescents
There is no specific recommendation for the use of Rivastigmina Sandoz in the pediatric population for the treatment of Alzheimer's disease.
Use of other medicines and Rivastigmina Sandoz
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medicine.
Rivastigmina Sandoz should not be administered at the same time as other medicines with similar effects to Rivastigmina Sandoz. Rivastigmina Sandoz may interfere with anticholinergic medicines (medicines used to relieve cramps or spasms, for the treatment of Parkinson's disease, or to prevent travel sickness).
Rivastigmina Sandoz should not be administered with metoclopramide (a medicine used to relieve or prevent nausea and vomiting). Taking both medicines together may cause problems such as stiffness of the limbs and tremor of the hands.
If you need to undergo surgery while taking Rivastigmina Sandoz, inform your doctor before any anesthetic is administered, as Rivastigmina Sandoz may exaggerate the effects of some muscle relaxants during anesthesia.
Be cautious when taking Rivastigmina Sandoz with beta-blockers (medicines, such as atenolol, used to treat hypertension, angina, and other heart conditions). Taking both medicines together may cause problems such as bradycardia (slow heart rate), leading to dizziness or loss of consciousness.
Be cautious when taking Rivastigmina Sandoz with other medicines that may affect heart rhythm or the electrical system of the heart (prolongation of the QT interval).
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medicine.
If you are pregnant, the benefits of using Rivastigmina Sandoz should be weighed against the possible effects on the fetus. Rivastigmina Sandoz should not be used during pregnancy, unless it is clearly necessary.
You should not breastfeed your children during treatment with Rivastigmina Sandoz.
Driving and operating machinery
Your doctor will tell you if your condition allows you to drive or use machinery safely. Rivastigmina Sandoz may cause dizziness and drowsiness, mainly at the start of treatment or when increasing the dose. If you feel dizzy or drowsy, do not drive, use machinery, or perform other tasks that require your attention.
Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Starting treatment:
Your doctor will tell you what dose of Rivastigmina Sandoz you should take.
Your doctor will regularly check if the medication is working for you. Your doctor will also monitor your weight while you are taking this medication.
If you have not taken Rivastigmina Sandoz for more than three days, do not take the next dose until you have consulted your doctor.
Taking this medication:
If you take more Rivastigmina Sandoz than you should:
If you accidentally take more Rivastigmina Sandoz than you should, inform your doctor. You may require medical attention. Some people who have taken accidental higher doses have experienced dizziness (nausea), vomiting, diarrhea, high blood pressure, and hallucinations.It may also cause a slowing of heart rate and fainting.
If you forget to take Rivastigmina Sandoz:
If you forget your dose of Rivastigmina Sandoz, wait and take the next dose at the usual time. Do not take a double dose to make up for the missed doses.
If you have any doubts about using this medication, consult your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
You may experience side effects more frequently when you first start taking your medicine or if your dose is increased. Side effects usually disappear gradually as your body gets used to the medicine.
Very common(may affect more than 1 in 10 patients)
• Dizziness
• Loss of appetite
•Stomach problems such asdizziness (nausea), vomiting, diarrhea
Common(may affect up to 1 in 10 patients)
• Anxiety
•Sweating
• Headache
• Burning sensation
• Weight loss
• Stomach pain
• Feeling of agitation
• Feeling of fatigue or weakness
• Feeling of general discomfort
• Tremor or feeling of confusion
• Decreased appetite
•Nightmares
Uncommon(may affect up to 1 in 100 patients)
• Depression
• Difficulty sleeping
•Blackouts or accidental falls
• Changes in liver function
Rare(may affect up to 1 in 1000 patients)
•Chest pain
•Skin rash, itching
• Seizures (convulsions)
•Ulcersin your stomach or intestine
Very rare(may affect up to 1 in 10000 patients)
•High blood pressure
•Urinary tract infection
• Seeing things that do not exist (hallucinations)
•Problemswith your heart rhythm such as rapid or slow heart rate
•Gastrointestinal bleeding – presents as blood in the stool or vomiting blood
•Pancreatitis – symptoms include severe pain in the upper stomach, often with dizziness (nausea) or vomiting
•Worsening of Parkinson's disease symptoms or development of similar symptoms–such as muscle rigidity, difficulty moving, and muscle weakness
Not known(frequency cannot be estimated from available data)
•Intense vomiting that may cause tearing of part of the digestive tube that connects your mouth to your stomach (esophagus)
•Dehydration (loss of a large amount of fluid)
•Liver disorders (yellowing of the skin, yellowing of the white of the eyes, abnormal darkening of the urine or unexplained nausea, vomiting, fatigue, and loss of appetite)
•Aggression, feeling of restlessness
•Irregular heart rhythm
Patients with dementia or Parkinson's disease
These patients experience some side effects more frequently and also have some additional side effects:
Very common(may affect more than 1 in 10 patients)
• Tremor
• Blackouts
• Accidental falls
Common(may affect up to 1 in 10 patients)
• Anxiety
• Feeling of unease
• Irregular heart rhythm and slow or fast heart rate
• Difficulty sleeping
• Excessive saliva and dehydration
• Abnormally slow or uncontrolled movements
•Worsening of Parkinson's disease symptoms or development of similar symptoms–such as muscle rigidity, difficulty moving, and muscle weakness
Uncommon(may affect 1 in 100 patients)
•Irregular heart rhythm and poor movement control
Other side effects observed in transdermal patches and may appear with hard capsules:
Common(may affect up to 1 in 10 patients)
• Fever
• Severe confusion
• Urinary incontinence (inability to retain urine)
Uncommon(may affect up to 1 in 100 patients)
• Hyperactivity (elevated level of activity, agitation)
Not known(frequency cannot be estimated from available data)
•Allergic reaction at the patch application site, such as blisters or skin inflammation
If you experience any of these side effects, contact your doctor as they may require medical assistance.
Reporting side effects
If you experienceany type of side effect, consult your doctor or pharmacist, even if it is apossibleside effect that does not appear in this prospectus.You can also report them directly tothrough theSpanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use Rivastigmina Sandoz after the expiration date that appears on the blister pack, bottle, and box after “EXP” or “CAD”. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through drains or in the trash.Ask your pharmacist how to dispose ofthe packaging and the medicines that you no longerneed.By doing so, you will help protect the environment.
Do not store at a temperature above 30°C.
Composition of Rivastigmina Sandoz
-The active ingredient is rivastigmine.
-The other components are hypromellose, magnesium stearate, microcrystalline cellulose, colloidal silica, gelatin, yellow iron oxide, red iron oxide, titanium dioxide, and shellac.
Each capsule of Rivastigmina Sandoz 1.5 mg contains 1.5 mg of rivastigmine.
Each capsule of Rivastigmina Sandoz 3 mg contains 3 mg of rivastigmine.
Each capsule of Rivastigmina Sandoz 4.5 mg contains 4.5 mg of rivastigmine.
Each capsule of Rivastigmina Sandoz 6 mg contains 6 mg of rivastigmine.
Appearance of the product and contents of the pack
It is packaged in blisters and is available in three different presentations (28, 56 or 112 capsules).
Marketing Authorization Holder
Sandoz GmbH
Biochemiestraße 10
A-6250 Kundl
Austria
Responsible for manufacturing
Novartis Farmacéutica, S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain
Novartis Pharma GmbH
Roonstrasse 25
90429 Nuremberg
Germany
Salutas Pharma GmbH
Otto-Von-Guericke-Allee 1, Barleben,
Saxony-Anhalt, 39179,
Germany
For more information about this medicine, please contact the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien Sandoz N.V. Telecom Gardens, Medialaan 40 B 1800 Vilvoorde Tel: + 32 (0)2 722 97 97 | Luxembourg/Luxemburg Sandoz N.V. Telecom Gardens, Medialaan 40 B 1800 Vilvoorde Tel: + 32 (0)2 722 97 97 | |
Magyarországg Sandoz Hungária Kft. Bartók Béla út 43-47 H-1114 Budapest Tel.: + 36 1 430 2890 E-mail:[email protected] | ||
Czech Republic Sandoz s.r.o. Na Pankráci 1724/129 CZ-14000 Praha 4 - Nusle E-mail:[email protected] Tel: +420 225 775 111 | Malta V.J. Salomone Pharma Limited Upper Cross Road Marsa MRS 1542 Malta Tel: 00356 22983143 | |
Denmark Sandoz A/S Edvard Thomsen's Vej 14 DK-2300 København S Danmark Tlf: +45 6395 1000 | Netherlands Sandoz BV Hospitaaldreef 29, NL-1315 RC Almere Tel: + 31 36 5241600 E-mail:[email protected] | |
Germany Hexal AG Industriestraße 25 D-83607 Holzkirchen Tel: + 49 8024 908 0 E-mail: [email protected] | Norway Sandoz A/S Edvard Thomsen's Vej 14 DK-2300 København S Danmark Tlf: +45 6395 1000 | |
Estonia Sandoz d.d. Eesti filiaal Pärnu mnt 105 EE-11312 Tallinn Tel: +372 6652400 | Austria Sandoz GmbH Biochemiestrasse 10 A-6250 Kundl Tel: + 43 (0)53382000 | |
Greece SANDOZ HELLASMONOPROSOPI A.E. Tel: +30 216 600 5000 | Poland Sandoz Polska Sp.z o.o. ul. Domaniewska 50 C PL-02-672 Warszawa Tel: + 48 22 549 15 00 | |
Spain Sandoz Farmacéutica, S.A Centro Empresarial Parque Norte,Edificio Roble C/ Serrano Galvache Nº 56, 28033 Madrid Tel: +34900 456 856 | Portugal Sandoz Farmacêutica, Lda. Quinta da Fonte, Rua dos Malhões nº5, Edifício Q56 D. Pedro I, Piso 0 2770-071 Paço de Arcos Portugal Tel: +351 211 964 000 | |
France Sandoz SAS 49, avenue Georges Pompidou F-92593 Levallois-Perret Cedex Tél: + 33 1 4964 4800 | Romania SC Sandoz S.R.L. Str Livezeni nr. 7A, Târgu Mure?, 540472 România Tel: +40 21 310 44 30 | |
Ireland Rowex Ltd. Newtown IE-Bantry Co. Cork P75 V009 Tel: +353 27 50077 | Slovenia Lek Pharmaceuticals d.d. Verovskova 57 SI-1526 Ljubljana Tel: + 386 1 5802111 E-mail:[email protected] | |
Island Sandoz A/S Edvard Thomsen's Vej 14 DK-2300 København S Danmark Tlf: +45 6395 1000 | Slovakia Sandoz d.d. - organisational unit Žižkova 22B SK-811 02 Bratislava Tel: +421 2 48 200 600 | |
Italy Sandoz S.p.a Largo Umberto Boccioni 1 I-21040 Origgio (VA) Tel: +39 02 96541 | Finland Sandoz A/S Edvard Thomsen's Vej 14 DK-2300Kööpenhamina S/Köpenhamn S Tanska/Danmark Puh: +358 010 6133 400 info.suomi@sandoz.com | |
Cyprus Π.Τ.Χατζηγeωργ?ουεταιρε?αLtd Γιλντ?ζ31-3042Λεμεσ?ς Τηλ?φωνο: 00357 25372425 Φαξ: 00357 25376400 e-mail: [email protected] | Sweden Sandoz A/S Edvard Thomsen's Vej 14 DK-2300Köpenhamn S E-mail:[email protected] | |
Latvia Sandoz d.d. Latvia filiale K.Valdemara Str. 33 – 29 LV-1010 Riga Tel: + 371 67892006 | United Kingdom (Northern Ireland) Sandoz Ltd Frimley Business Park Frimley Camberley Surrey GU16 7SR Tel: +44 1276 69 8020 E-mail:[email protected] | |
Lithuania Sandoz Pharmaceuticals d.d., Branch Office Lithuania Seimyniskiu Str. 3A LT-09312 Vilnius Tel: + 370 5 2636037 | Croatia Sandoz d.o.o. Maksimirska 120 10 000 Zagreb Tel: +38512353111 E-mail: [email protected] |
This leaflet was revised inNovember 2024
For more detailed information about this medicine, please visit the website of the European Medicines Agencyhttp://www.ema.europa.eu
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.